Skip to main content

Table 1 Clinical and MRI parameters at diagnosis and at the enrolment (whole population)

From: Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study

 

OCB+

OCB−

Whole group

p value

N (f/m)

50 (34/16)

40 (28/12)

90 (62/28)

0.511

Age (years)

42.5 ± 10.4 (19–67)

42.4 ± 11.2 (17–69)

42.5 ± 10.7 (17–69)

0.943

Years from onset to diagnosis

3.0 ± 5.1 (0–21)

2.6 ± 3.9 (0–17)

2.8 ± 4.6 (0–21)

0.356

Years from diagnosis to enrolment

7.8 ± 5.2 (0–20)

7.9 ± 6.4 (0–22)

7.9 ± 5.7 (0–22)

0.918

Years from onset to enrolment (disease duration)

10.8 ± 7.0 (1–31)

10.5 ± 7.3 (1–29)

10.7 ± 7.1 (1–31)

0.878

EDSS at diagnosis

1.5 (0–3.0)

1.0 (0–3.5)

1.5 (0–3.5)

0.645

EDSS at enrolment

2.8 (1.0–8.0)

1.5 (0–6.5)

2.0 (1.0–8.0)

<0.0001

RRMS/SPMS at enrolment

35/15

36/4

71/19

0.018

Time to SPMS transition in months

123 ± 23 (98–187)

183 ± 13 (165–198)

136 ± 33 (98–198)

<0.0001

Cognitive impairment CN/mCI/sCI

30/9/11

34/5/1

64/14/12

0.013

CL number at enrolment

6.1 ± 6.1 (0–24)

2.2 ± 2.8 (0–11)

4.4 ± 5.3 (0–24)

<0.0001

WMLV at enrolment (cm3)

7.1 ± 3.6 (1.1–16.4)

6.5 ± 4.1 (1.3–18.1)

6.8 ± 4.0 (1.1–18.1)

0.258

Treatment until now

 None

0

5

5

0.033

 Only 1° linea

34

28

62

 At least 2° linea

11

6

17

 At least 3° linea

5

1

6

  1. EDSS Expanded Disability Status Scale, RRMS relapsing-remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, CN cognitively normal, mCI mild cognitive impairment, sCI severe cognitive impairment, CL cortical lesion, WML white matter lesion
  2. Data are reported as mean ± standard deviation (range). For the EDSS, median and (range) are provided
  3. a1° line drugs: IFN-beta, GA, azathioprine; 2° line drugs: fingolimod, natalizumab; 3° line drug: cyclophosphamide, mitoxantrone